?
Parsey Merdad
Chief Medical Officer
Gilead Sciences, Inc.
US, Foster City [HQ]
CIK
1792150
Data Source
We automatically created this profile. The information was aggregated based on earnings call transcripts, insider forms and DEF 14A statements.
Latest Information
Shares :
96,380
Price per Share :
$91.84
Equivalence :
$8,851,539.20
Transaction History
-
S96,380 Shares After TransactionValue : $6,614,559.40Sold $137,260.00Transaction Date : 07/01/24
-
Footnotes
-
-
Footnotes:#1 The sale transaction reported in this Form 4 is made pursuant to a Rule 10b5-1 trading plan adopted on November 9, 2023.
-
A69,701 Shares After TransactionValue : $n/a$0.0Transaction Date : 01/31/24
-
Footnotes
-
-
Footnotes:#1 Represents shares of the Issuer's common stock subject to specific tranches of the performance share awards made to the Reporting Person on March 10, 2022 and March 10, 2023. Such tranches of shares were subject to both performance-vesting and service-vesting requirements. The performance vesting requirement was satisfied on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation and Talent Committee of the Issuer's Board of Directors. However, the shares will not be issued to the Reporting Person until the requisite continuing service requirements are also met.#2 Represents shares of the Issuer's common stock subject to specific tranches of the performance share awards made to the Reporting Person on March 10, 2021. Such tranches of shares were subject to both performance-vesting and service-vesting requirements. The performance vesting requirement was satisfied on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation and Talent Committee of the Issuer's Board of Directors.
-
A126,325 Shares After TransactionValue : $n/a$0.0Transaction Date : 01/31/24
-
Footnotes
-
-
Footnotes:#1 Represents shares of the Issuer's common stock subject to specific tranches of the performance share awards made to the Reporting Person on March 10, 2022 and March 10, 2023. Such tranches of shares were subject to both performance-vesting and service-vesting requirements. The performance vesting requirement was satisfied on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation and Talent Committee of the Issuer's Board of Directors. However, the shares will not be issued to the Reporting Person until the requisite continuing service requirements are also met.#2 Represents shares of the Issuer's common stock subject to specific tranches of the performance share awards made to the Reporting Person on March 10, 2021. Such tranches of shares were subject to both performance-vesting and service-vesting requirements. The performance vesting requirement was satisfied on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation and Talent Committee of the Issuer's Board of Directors.
-
F102,616 Shares After TransactionValue : $8,030,728.16$1,855,466.34Transaction Date : 01/31/24
-
Footnotes
-
-
Footnotes:#1 Represents shares of the Issuer's common stock subject to specific tranches of the performance share awards made to the Reporting Person on March 10, 2022 and March 10, 2023. Such tranches of shares were subject to both performance-vesting and service-vesting requirements. The performance vesting requirement was satisfied on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation and Talent Committee of the Issuer's Board of Directors. However, the shares will not be issued to the Reporting Person until the requisite continuing service requirements are also met.#2 Represents shares of the Issuer's common stock subject to specific tranches of the performance share awards made to the Reporting Person on March 10, 2021. Such tranches of shares were subject to both performance-vesting and service-vesting requirements. The performance vesting requirement was satisfied on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation and Talent Committee of the Issuer's Board of Directors.
-
S100,936 Shares After TransactionValue : $7,386,496.48Sold $146,360.00Transaction Date : 02/28/24
-
Footnotes
-
-
Footnotes:#1 The sale transaction reported in this Form 4 is made pursuant to a Rule 10b5-1 trading plan adopted on November 9, 2023.#2 Sale prices reported for the transactions reported here range from $72.454 to $72.88. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request.#3 Balance adjusted to reflect shares acquired under the Gilead Sciences, Inc. Employee Stock Purchase Plan.